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Background: The role of surgical resection in the treatment of primary gastric lymphoma (PGL) remains
unclear. This retrospective study evaluated the clinical outcome of PGL treated with chemotherapy alone or
surgery followed by chemotherapy.
Methods: During 1986–2003, 59 patients with PGL (other than mucosa-associated lymphoid tissue type
lymphoma) were identified from hospital files. The medical records, pathologic sections, radiographic images
and treatment modalities of these patients were reviewed. Patients were categorized into localized (stage IE
and IIE-1) and advanced (stage IIE-2 or beyond) stage groups. Survival was estimated by the Kaplan-Meier
method.
Results: The study included 55 patients who received treatment at the same institute. Among them, 32 had
localized PGL (15 stage IE, 17 stage IIE-1) and 23 had advanced disease. The median survival of the localized
stage group was not reached during a mean follow-up of 168.1 ± 16.7 months (95% confidence interval [CI],
135.4–200.8 months), while that of the advanced stage group was 33.0 ± 6.8 months (95% CI, 19.7–46.5;
p < 0.001, log-rank test). Among patients with localized PGL, the 5-year overall survival rate of those
receiving chemotherapy alone (n = 19) or combination therapy (surgery followed by chemotherapy, n = 13)
was 73.4% and 87.5%, respectively (p = 0.229). The 5-year disease-free survival was 68.4% and 84.6%,
respectively (p = 0.540). However, post-chemotherapy life-threatening hemorrhage occurred in five of the
32 patients (15.6%) in the localized stage group: four in the chemotherapy-alone group, and one in the
combination therapy group, all of whom had failed to achieve complete response.
Conclusion: The clinical outcome of localized PGL treated by chemotherapy alone is similar to that treated
by surgery followed by chemotherapy in terms of tumor response, disease-free survival and overall survival,
suggesting that surgery be reserved for those with residual tumors after chemotherapy. [ J Formos Med Assoc
2006;105(3):194–202]
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Over the last two decades, the management of
gastric lymphoma has continued to evolve, and
the role of surgical resection of the stomach ap-
pears to be diminishing, and may no longer
even be defined as a routine treatment modality
in large prospective randomized trials. Primary
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gastric lymphoma (PGL) is not a common ma-
lady, accounting for perhaps 10–15% of all non-
Hodgkin’s lymphoma cases.1 Our review of the
literature found that most of the relevant studies
of the treatment and outcome of PGL featured
smal l  numbers  o f  pa t i en t s  and  were
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adequate pathologic material for review (according
to the Revised European American Lymphoma/
World Health Organization classification14); com-
plete clinical information including prompt stag-
ing procedures; primary treatment with adequate
follow-up in our hospital. Patients with mucosa-
associated lymphoid tissue (MALT) lymphoma
were excluded.
Clinical evaluations
Staging work-up included detailed physical
examination, inspection of Waldeyer’s ring, com-
puted tomography (CT) of the abdomen, small-
bowel series, barium enema study of the colon and
rectum, gallium-67 scan, and bone marrow aspi-
ration and biopsy.13 Chest CT was not routinely
performed in all patients. Patients received follow-
up endoscopy with biopsy and CT scan of the ab-
domen after every 2–3 cycles of chemotherapy to
evaluate tumor response.
Classification of the tumor stage was according
to Musshoff ’s modification of the Ann Arbor stag-
ing system.15 Stage IE is when the tumor remains
confined within the stomach; stage IIE-1 is when
there is perigastric nodal involvement only; stage
IIE-2 is when there is more distant nodal involve-
ment below the diaphragm; stage IIIE denotes nod-
al involvement above and below the diaphragm;
and stage IV denotes multiple visceral organ in-
volvement.
Grading of treatment toxicity as well as tumor
response were evaluated according to the criteria
defined by the World Health Organization.16 All
tumors were evaluated by abdominal/chest CT and
endoscopy. Complete response (CR) was defined
as the disappearance of all evidence of tumor(s)
for a duration of at least 4 weeks. Partial response
(PR) was defined as > 50% reduction in the sum
of the products of the longest perpendicular dia-
meters of all measurable lesions in radiographic
images, with the reduction lasting at least 4 weeks.
Stable disease (SD) was defined as < 50% reduc-
tion or < 25% increase in the sum of the products
of the longest perpendicular diameters of all meas-
urable lesions, lasting > 4 weeks. Patients with
progressive lesions were not classified as having
conducted retrospectively during the 1980s and
1990s.2–5 Moreover, many investigators continue
to advocate surgical resection to debulk the mass,
accurately stage the lesion, and prevent perfora-
tion.6–8 During the early 1990s, some researchers
suggested that chemotherapy alone was effective
and may also be sufficient to prevent morbidity
associated with gastrectomy.2,4 This led to increased
support for gastric preservation in the treatment
of subsequent residual disease. Other researchers,
however, recommended surgery as curative for
PGL, particularly for stage IE disease.9,10 Those
researchers who advocated surgery either with
or without associated chemotherapy focused on
accurate tumor staging and the association of this
treatment with less hemorrhage or stomach per-
foration; although with the advent of endoscopic
ultrasound, laparotomy biopsy is no longer war-
ranted.9 Most studies have revealed a rather low
incidence of severe hemorrhage or perforation, ac-
counting for 2.1% and 1.7%, respectively, of those
individuals treated with chemotherapy alone, and
2.2% and 0.9%, respectively, of surgically-treated
individuals.11,12 Such evidence suggests that the
role of surgery in the treatment of PGL may be less
important than previously considered.
Whether or not a PGL patient is referred to a
medical oncologist or a surgeon thus appears to
depend on the gastroenterologist’s point of view.13
This study retrospectively examined the impact
of different therapeutic modalities on the treatment
outcome for PGL performed at a single medical in-
stitution in Taiwan between 1986 and 2003.
Methods
Patients
The records of all patients with newly diagnosed
PGL in our hospital from July 1986 to June 2003
were reviewed. The inclusion criteria were: histo-
logically proven malignant lymphoma that was
considered to originate from the stomach because
of predominant gastric lesions (for stage IE–IIE-2
diseases) or presenting with upper gastrointestinal
symptoms and signs (for stage IIIE–IVE diseases);
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PR or SD. Progressive disease (PD) was defined as
the appearance of new lesions or > 25% increase
in the area(s) of original measurable disease.
Statistical analysis
Comparisons between discrete variables were
performed using Student’s t test. In the analysis
of overall survival, an event was defined as death
from any cause. Disease-free survival was calcu-
lated from the date of complete remission or sur-
gery to the date of tumor relapse defined by the
results of imaging studies or endoscopic biopsy.
The survival distribution of disease-free survival
and overall survival were estimated by the method
of Kaplan and Meier,17 and compared by log-rank
test. The association of prognostic factors with sur-
vival was estimated with Cox’s proportional haz-
ards model and expressed as relative risk
with 95% confidence interval (CI).18 Model selec-
tion for identifying the variables with an effect on
survival was based on a forward stepwise pro-
cedure, with p values of 0.05 and 0.06 being en-
tered or removed, respectively. The tested variables
for localized disease were gender, age (< 60, * 60
years old), international prognostic index (IPI)
score19 ) 1 vs. > 1, stage of disease (IE vs. IIE-1),
extent of gastric involvement (< 5 cm vs. * 5 cm),
and calendar year of diagnosis (before 2000 vs.
2000 or beyond). All p values were two-tailed and
a p value < 0.05 was considered to be statistically
significant. SPSS version 10.0 (SPSS Inc, Chicago,
IL, USA) was used for all statistical analyses.
Results
Fifty-nine consecutive patients who fulfilled the
broad-spectrum diagnostic criteria for PGL, ex-
cluding those with MALT lymphoma, were iden-
tified by a review of the files. The diagnosis was
made by upper gastrointestinal endoscopic biop-
sy in 52 patients and by laparoscopy in three. Four
patients who did not receive active treatment or
had prompt loss of follow-up after the diagnosis
were subsequently excluded from the analysis. Of
the 55 patients (26 men, 29 women) included in
the study, 38 who received chemotherapy alone
were categorized into the chemotherapy group, and
the other 17 who received surgery (13 subtotal
gastrectomy plus D1 nodal dissection, 4 total gas-
trectomy) followed by chemotherapy were cate-
gorized into the combined treatment group.
The chemotherapy regimen was mainly CHOP
(cyclophosphamide, doxorubicin, vincristine,
prednisone; n = 32) or CEOP (cyclophosphamide,
epirubicin, vincristine, prednisone; n = 20), which
consisted of intravenous injection of cyclophos-
phamide 750 mg/m2, doxorubicin 50 mg/m2 or
epiubicin 60 g/m2, and vincristine 1.4 mg/m2
(maximum 2 mg) on day 1, and prednisone 60
mg/m2 orally on days 1–5. The treatment was
given every 21–28 days as one cycle, for a total of
4–8 cycles. Other chemotherapy regimens were
m-BACOD (methotrexate, bleomycin, cyclophos-
phamide, vincristine, dexamethasone) in two
patients and COP (cyclophosphamide, vincristine,
prednisone) in one. Palliative radiotherapy was
given in one patient with advanced PGL in the
combined treatment group.
The demographic and clinicopathologic char-
acteristics of the two groups of patients are listed
in Table 1. Diffuse large B-cell lymphoma was
the most common (80%) histologic type. Among
the 32 patients with stage IE–IIE-1 disease, 19
received chemotherapy alone and 13 received
subtotal gastrectomy followed by chemotherapy.
Diagnosis was made before year 2000 in 11 pa-
tients in the combined treatment group; surgi-
cal intervention for stage IE/IIE-1 disease was per-
formed after 2000 in only two patients with an
initial diagnosis of poorly differentiated carcino-
ma by histologic examination of endoscopic bi-
opsy specimen. Among the 23 patients with stage
IIE-2 disease or beyond, 19 received chemothera-
py alone while four underwent debulking surgery
before chemotherapy because of uncontrolled
upper gastrointestinal tract bleeding (2 patients),
gastric outlet obstruction (1) and for diagnostic
purposes (1).
Adverse events
Grade 3–4 neutropenia occurred in 13.2% of pa-
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tients in the chemotherapy and 17.6% of patients
in the combined treatment group; thrombocyto-
penia occurred in 2.6% and 5.9% of patients,
respectively, in the two groups.
Three of 32 stage IE/IIE-1 patients developed
sepsis, bacteremia or pneumonia. Nine of 32
stage IIE-2–IV patients developed serious in-
fection (including the 5 patients with gastric
perforation), all of whom had resulting fatal
outcome. Six of the nine stage IIE-2–IV patients
with serious infectious complications were aged
over 65 years.
Severe upper gastrointestinal tract hemorrhage
occurred in 15.6% (5/32) of stage IE/IIE-1 patients,
including four in the chemotherapy group and
one in the combined treatment group. The hem-
orrhage events were associated with fatality in
three patients in the chemotherapy group, with a
median survival of 3 months. Nine of stage IIE-2–
IV patients suffered severe hemorrhagic complica-
tions during chemotherapy; five of them died af-
ter developing perforation. The tumor response and
treatment-related complications are summarized
in Table 2.
Tumor response and survival
Among those evaluable for chemotherapy re-
sponse, CR was achieved in 84.2% (16/19 in the
chemotherapy group) of stage IE/IIE-1 patients and
in 30.4% (7/23 of both groups) of stage IIE-2–IV
patients. The treatment response was durable in
early-stage patients, with 5-year disease-free
survival of 68.4%. On the contrary, four of seven
advanced-stage complete responders had tumor
recurrence within 4 years, with a 5-year disease-
free survival of 15.8% (3/19).
At a median follow-up of 42 months (range,
1–128 months), the median overall survival had
not been reached in the chemotherapy group
(median follow-up, 34.5 months; 95% CI, 2.25–
Table 1. Demographic and clinicopathologic characteristics of patients with localized and advanced primary gastric
lymphoma treated with chemotherapy alone or surgery followed by chemotherapy (combined treatment)
Stage IE / IIE-1 (n = 32) Stage IIE-2 – IV (n = 23) Total (n = 55)
Chemotherapy Combined
p
Chemotherapy Combined
p
Chemotherapy Combined
p
(n = 19) (n = 13) (n = 19) (n = 4) (n = 38) (n = 17)
Gender, n (%) 0.60 0.05 0.23
Male 07 (36.8) 06 (46.2) 13 (68.4) 00 20 (52.6) 06 (35.3)
Female 12 (63.2) 07 (53.8) 06 (31.6) 4 (100) 18 (47.4) 11 (64.7)
Age, yr 0.06 0.56 0.11
Median 59 45 60 69 60 46
95% CI 41.02–72.13 36.85–58.21 45.25–72.32 49.58–76.92 43.26–72.10 38.28–64.18
Gastric lesion, n (%) 0.13 0.48 0.23
Size ) 5 cm 12 (63.2) 09 (69.2) 06 (31.6) 2 (50.0) 18 (47.4) 11 (64.7)
Size > 5 cm 07 (36.8) 04 (30.8) 13 (68.4) 2 (50.0) 20 (52.6) 06 (35.3)
Diagnosis, n (%) 0.03 0.19 0.03
Before 2000 09 (47.3) 11 (84.6) 13 (68.4) 4 (100) 22 (57.9) 15 (88.2)
2000 or after 10 (52.7) 02 (15.4) 06 (31.6) 00 16 (42.1) 2 (11.8)
Histology, n (%) 0.70 0.29 0.51
DLBCL 15 (78.9) 11 (84.6) 14 (73.7) 4 (100) 29 (76.3) 15 (88.2)
Diffuse mix 03 (15.8) 02 (15.4) 1 (5.3) 00 04 (10.5) 02 (11.8)
Others 1 (5.3) 00 04 (21.0) 00 05 (13.2) 00
IPI score, n (%) 0.40 0.97 0.08
0–1 14 (73.7) 12 (92.3) 03 (15.8) 00 17 (44.7) 12 (70.6)
* 2 05 (26.3) 1 (7.7) 16 (84.2) 4 (100) 21 (55.3) 05 (29.4)
CI = confidence interval; DLBCL = diffuse large B cell lymphoma; IPI = international prognostic index.
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74.14), while it was 62 months (95% CI, 17.40–
147.12) in the combined treatment group (p <
0.001, log-rank test). The 5-year overall survival
rate of stage IE/IIE-1 patients in the chemotherapy
group was 73.4%, and it was 87.5% in the com-
bined treatment group (p = 0.229, log-rank test;
Figure 1). The 5-year disease-free survival rate
in the corresponding patient groups was 68.4%
and 84.6%, respectively (p = 0.540, log-rank test).
The disease-free survival curves of stage IE/IIE-1
patients are shown in Figure 2. The overall surviv-
al curves of both localized (stage I–IIE-1) and ad-
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Figure 1. Overall survival of localized primary gastric lymphoma.
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Figure 2. Disease-free survival of localized primary gastric
lymphoma.
Table 2. Tumor response and treatment-related complications of primary gastric lymphoma
Stage IE / IIE-1 (n = 32) Stage IIE-2 – IV (n = 23) Total (n = 55)
Chemotherapy Combined
p
Chemotherapy Combined
p
Chemotherapy Combined
p
(n = 19) (n = 13) (n = 19) (n = 4) (n = 38) (n = 17)
Tumor response, n (%) 0.50 0.48 0.29
CR 16 (84.2) 12 (92.3) 06 (31.6) 1 (25.0) 22 (57.9) 13 (76.5)
PR 03 (15.8) 1 (7.7) 09 (47.4) 1 (25.0) 12 (31.6) 02 (11.8)
SD / PD 00 00 04 (21.0) 2 (50.0) 04 (10.5) 02 (11.8)
Anti-ulcer therapy during chemo, n (%)
19 (100). 11 (85.4) 0.31 19 (100). 4 (100). – 38 (100). 15 (88.2) 0.17
Grade 3–4 AE, n (%) 0.89 0.58 0.58
Hematologic
Neutrophils 02 (10.5) 1 (7.7) 03 (15.8) 2 (50.0) 05 (13.2) 03 (17.6)
Platelets 00 00 1 (5.3) 1 (25.0) 1 (2.6) 1 (5.9)
Infection 02 (10.5) 1 (7.7) 06 (31.6) 3 (75.0) 08 (21.0) 04 (23.5)
Tumor-related
Bleeding 04 (21.0) 1 (7.7) 06 (31.6) 3 (75.0) 10 (26.3) 4 (23.5)
Perforation 00 00 05 (26.3) 00 5 (13.2) 00
Follow-up, mo 0.054 0.295 < 0.001
Median 39 1080 21 14 34.5 62
95% CI 4.71–87.44 40.45–163.39 1.79–58.84 4.18–32.57 2.25–74.14 17.4–147.12
CR = complete remission; PR = partial remission; SD = stable disease; PD = progressive disease; AE = adverse event.
p = 0.540, log-rank test
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vanced (stage IIE-2–IV) PGL, regardless of treat-
ment modality, are shown in Figure 3.
Among stage IIE-2–IV patients, the median
survival of the combined treatment group was not
significantly different from that of the chemother-
apy group: 14 months (95% CI, 4.2–32.6 months)
versus 21 months (95% CI, 1.8–58.8 months; p =
0.295, log-rank test).
Univariate analysis by Cox’s proportional haz-
ards model showed that time to treatment (odds
ratio, 1.529; p = 0.046) and IPI (odds ratio, 1.384;
p = 0.051) were significant predictors of overall
survival for stage IE/IIE-1 patients; while time
of treatment (before 2000 vs. 2000 or after) was
the only independent predictor by multivariate
analysis. Gastric lesion size, age and gender were
not significantly associated with overall survival in
the univariate analysis.
Discussion
The optimal treatment for localized PGL remains
to be established. In the 1980s, gastrectomy was
used to treat PGL because of its low surgery-
related mortality (2–5%).20–24 A study from the
Mayo Clinic reported the 5-year-survival rate of
75% with curative resection, and 32% with pal-
liative resection.4 For stage IE PGL, the cure rate
was as high as 80%. However, because the suc-
cess of surgical management of PGL depends on
tumor size, the depth of its penetration into gas-
tric tissue, and the involvement of regional lymph
nodes,9,24,25 some investigators began using chemo-
therapy, mostly CHOP and its related regimens,
to control the tumors and prevent postoperative
morbidity.2,4,12 Maor et al showed that the 6-year
overall survival of patients treated with chemother-
apy alone was 76%.4 However, for bulky tumors,
the advantage of chemotherapy is overshadowed
by the potential for tumor bleeding and gastric
perforation. Therefore, some investigators sug-
gested that debulking surgery followed by chemo-
therapy might offer better tumor control with re-
duced complication rates.26–31 In the present series,
all five patients who developed gastric perforation
received chemotherapy alone, and eventually died
of this complication. In contrast, none of the pa-
tients who received combination therapy had this
complication, suggesting that surgery will con-
tinue to play an important role in PGL manage-
ment. Of note, gastrointestinal bleeding developed
at the time of disease progression in five patients
(4 in the chemotherapy group, 1 in the combined
treatment group).
The overall surgical morbidity (15.4%, 2/13)
and mortality (7.7%, 1/13) in this study are simi-
lar to the findings of Rackner et al.32 The notion
that the rate of surgical complications might off-
set the benefit expected from tumor control is fur-
ther supported by the results of Salles et al, who
showed that for localized PGL, surgical resection
prior to chemotherapy did not affect the complete
response rate, survival rate, or disease-free sur-
vival.2 Similar results have also been demonstrat-
ed in several studies in Asian patients and in the
Groupe d’Etude des Lymphomes Digestifs and
Groupe d’Etude des Lymphomes de l'Adulte
studies.31,33–37
Although recent studies of PGL surgery appear
to suggest its diminished role, it might enhance
the effects of chemotherapy in stage IE PGL.38,39
Patients treated with conservative surgery fol-
lowed by three cycles of chemotherapy had a bet-
ter 5-year survival rate than patients treated with
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Figure 3. Overall survival of advanced compared with localized
primary gastric lymphoma (PGL), regardless of treatment
modality.
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chemotherapy alone.23,24,26,29–31 Similarly, this study
found that patients treated with surgery followed
by chemotherapy tended to fare better than those
treated with chemotherapy alone. The lack of a sta-
tistical difference between the two groups might
be due to the small group sizes in this study.
This study also found an improved outcome in
patients who received treatment after the year 2000,
which may be attributable to better supportive care
and a more widespread use of granulocyte colony
stimulating factor for the treatment of febrile
neutropenia. A subgroup of patients was identi-
fied who might be more likely to develop chemo-
therapy-induced life-threatening complications.
Often treated in an outpatient setting, these pa-
tients failed to achieve a complete response to
chemotherapy. To avoid such severe complications,
we recommend re-evaluating patients by endo-
scopy after two cycles of chemotherapy. At the
same time, patients should be warned that com-
plications such as gastric perforation and bleeding
are possible, and awareness programs involving
comprehensive education should be part of the
treatment process.
In this series, overall survival was significantly
lower for patients with advanced PGL than local-
ized PGL, signifying again that stage is an im-
portant prognostic factor in the treatment of PGL.
In the chemotherapy group, three of seven ad-
vanced PGL patients with complete response (3/
19, 15.8%) were long-term survivors (disease-free
survival > 6 years), while all four patients in the
combined-modality group died. The outcome of
combined therapy was dismal due to the higher
incidence of treatment-related tumor bleeding
(75%) and febrile neutropenia (50%) than in
the chemotherapy group (31.6% and 15.8%, re-
spectively). Analysis of median overall survival
showed that patients in the chemotherapy group
survived longer than those in the combined treat-
ment group, with median overall survival for ad-
vanced PGL of 21 months and 14 months, re-
spectively (p = 0.295). However, the four non-
survivors in the combined treatment group all
had IPI * 2 and were treated before 2000. One of
the four patients with advanced PGL who received
combined therapy achieved complete response
and survived for 39 months. The role of surgery
was limited in the treatment of advanced PGL
in this series. It is noteworthy that no patients in
this series received stem cell transplantation as
primary or salvage treatment. While combination
chemotherapy may currently be regarded as
the standard of care, the outcome of advanced
PGL might be improved if stem cell transplanta-
tion could be integrated into the treatment, espe-
cially in patients with chemotherapy-sensitive
relapse.
In summary, this study suggests that the clin-
ical outcome of localized PGL treated by chemo-
therapy alone is comparable to that treated by sur-
gery combined with chemotherapy in terms of
tumor response, disease-free survival and over-
all survival. We may presume, however, that organ
function is better preserved by chemotherapy alone
than surgery. The role of surgery for advanced PGL
has become less important than chemotherapy.
However, surgery could be reserved for those with
residual tumors after chemotherapy.
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